Home
RSSThe high cost of biotechnology drugs has been pinching the public and biotechnology companies realizing this are making an effort towards making these products more affordable.
Here are some of the examples which would make you believe what I am..
Related Stories
Most Recent
Most Popular
Most Commented
1
Star It 
(0)
AP, Geneva
Switzerland’s Roche said Thursday it has agreed to buy all the remaining shares in Genentech for $46.8 billion in a takeover described as the largest in Swiss...
made popular Mar 12 2009
AP, Basel
Roche says it has agreed to buy the remaining shares of Genentech for $46.8 billion in what is being described as the largest takeover in Swiss corporate history.
made popular Mar 12 2009
AP, New York
Genentech’s board of directors is close to striking a $95-per-share deal to sell itself to cancer drug partner Roche, according to a report by the Wall Street...
made popular Mar 9 2009
AP, New York
Swiss drug developer Roche is boosting its hostile tender offer for biotechnology pioneer Genentech by 7.5 percent to $93 per share.
made popular Mar 6 2009
AP, New York
Genentech Inc. on Monday touted its culture of innovative research and offered detailed long-term sales projects as it made its case to Wall Street on what it considers...
made popular Mar 2 2009
AP, New York
Genentech Inc. says its shareholders should reject a hostile buyout bid from Swiss drugmaker Roche.
made popular Feb 23 2009
AP, Washington
Three patients taking a Genentech drug have died of a rare brain infection, a known risk with the skin-clearing treatment, according to federal health officials.
made popular Feb 19 2009
AP, New York
Roche’s hostile bid for Genentech Inc., which became official late Monday, revealed just how far apart the companies are on valuing Genentech, with the...
made popular Feb 10 2009
AP, New York
Swiss drugmaker Roche on Monday officially launched its $42 billion hostile offer for the 44 percent of Genentech Inc. it doesn’t already own.
made popular Feb 9 2009
AP, New York
Roche Chief Executive Severin Schwan said Friday the company’s surprisingly low hostile $86.50-per-share offer for biotech giant Genentech Inc. is fairly priced...
made popular Feb 6 2009
AP, Basel
Swiss pharmaceuticals company Roche Holding AG made a fresh bid to buy U.S.-based Genentech Inc. Friday by offering $86.50 per share _ $2.50 less than its previous...
made popular Jan 30 2009
AP, South San Francisco
Biotechnology company Genentech Inc.’s fourth-quarter profit fell short of Wall Street expectations, despite a 47 percent boost from higher sales of the...
made popular Jan 15 2009
AP, New York
Genentech says fourth-quarter profit rose 47 percent on a boost in sales of its key cancer drug Avastin, but the results and the 2009 outlook are shy of Wall Street...
made popular Jan 15 2009
AP, New York
The Food and Drug Administration said Thursday it will update the labeling of Genentech Inc.’s psoriasis drug Raptiva to highlight the risk of several bacterial...
made popular Oct 16 2008
AP, New York
In an Oct. 14 story about Genentech’s third-quarter results, The Associated Press erroneously reported financial forecasts by analysts surveyed by Thomson...
made popular Oct 16 2008
AP, New York
Genentech says its third-quarter profit rose 6.7 percent on rising sales of key cancer drugs, in line with Wall Street forecasts.
made popular Oct 14 2008
AP, Washington
Federal regualtors said Thursday one case of a deadly brain infection has been reported in a patient taking Genentech and Biogen Idec’s blockbuster arthritis and...
made popular Sep 11 2008
AP, New York
Biotechnology giant Genentech is turning down a buyout offer from its majority owner Roche, saying the $43.7 billion takeover bid undervalues the company.
made popular Aug 13 2008
AP, San Francisco
Biotechnology pioneer Genentech Inc. mulled Roche Holding’s $43.7 billion offer for its remaining shares Monday as investors made clear their feelings that the...
made popular Jul 21 2008
AP, Geneva
Swiss drugmaker Roche on Monday offered $43.7 billion for the remaining shares of its U.S. biotech partner Genentech Inc. in a move to boost its stature in the market...
made popular Jul 21 2008
All Stories
Most Recent
Most Popular
Most Commented
